AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally. It provides medicines for cardiovascular, renal, metabolic, and immunological conditions; oncology medicines under the TAGRISSO, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and respiratory medicines under the Symbicort and Fasenra brand names. The company also offers medicines for diabetes; and clinical trial services. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.
| Current Price | ₹8,440.00 |
|---|---|
| Market Cap | ₹21,302 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Pharmaceutical Products |
| P/E Ratio | 113.6 |
| Return on Equity | 22.82% |
| 52-Week Range | ₹7,551.50 – ₹9,849.50 |
| Beta (1Y) | 0.51 |
| Dividend Yield | 0.38% |
1. Healthcare-100%
Astrazeneca Pharma India Ltd. is trading at ₹8,440.00, with a market capitalisation of ₹21,302 Cr.
Astrazeneca Pharma India Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Pharmaceutical Products).
Astrazeneca Pharma India Ltd. has a P/E of 113.6 and a return on equity of 22.82%.